Mirum wins FOP approval and posts strong AZURE-1 HDV result

Mirum is moving from a commercial rare-disease base into a broader, multi-product platform: it already sells LIVMARLI, CHOLBAM and CTEXLI, while building late-stage programs in HDV, cholestatic liver disease and FOP. The filing materially advances that expansion on two fronts. FDA approval of Atebrioz gives Mirum a second near-term commercial launch, with U.S. availability expected in October; the approval itself was not a surprise because the September 26, 2026 priority-review date was already known, so this is partly confirmation rather than a wholly new event. 〔0〕

The bigger incremental signal is brelovitug’s AZURE-1 result. In a pivotal study, 56% of patients on 300 mg weekly and 45% on 900 mg every four weeks achieved the combined virologic-response and ALT-normalization endpoint, versus 0% for delayed treatment, with p<0.0001 for both comparisons. The direction was partly anticipated from earlier AZURE-1 data, but a positive Phase 3 result across both doses substantially de-risks the program and moves it toward the remaining pivotal AZURE-4 readout and a planned BLA in the first half of 2027.

The filing strengthens the portfolio, but does not finish the HDV story. AZURE-1 is only one of two Phase 3 studies intended for the U.S. registration package, and full results have not yet been presented; the second pivotal study remains the key validation step. The company’s more than $1 billion brelovitug revenue estimate and more than $200 million Atebrioz estimate are management projections, not demonstrated sales. Bottom line: This is a meaningful pipeline-to-commercial step-up: a scheduled FOP approval becomes a launch, while a strong first pivotal HDV result materially improves the case for a second major product. The remaining AZURE-4 result still matters for registration certainty.